Our Research

The Kwon Research Group investigates polymeric nanotechnology to formulate, target, and enhance properties of anticancer and antifibrotic drugs. Polymeric nanoparticles and polymeric conjugates prolong circulation in blood, enhance potency, and reduce toxicity of potent yet toxic anticancer drugs and biologics. Our aim is to devise safe and effective nanomedicines for cancer and fibrosis that can be translated into humans for clinical trials, hopefully saving lives.

 

Grants

  • NIH R01CA257837
  • NIH R21CA252579
  • DoD PRMR Program – Submitted

Core Focus Areas

Polymeric nanoparticles for cancer therapy

The objective of this focus area is to formulate anticancer nanoparticles to lower toxicity and enhance potency of a repertoire of poorly water-soluble anticancer drugs. We focus on a novel prodrug strategy for polymeric nanoparticles, seeking delayed-release and enhanced delivery into solid tumors. See an example of our work in this area here.

NIH R01CA257837
04/01/2021 – 03/31/2025

Water-soluble polymer-peptide biologics for fibronectin targeting in breast cancer

The objective of this focus area is to investigate water-soluble PEGylated peptides for the imaging and treatment of breast cancer, focusing on targeting the extracellular matrix of solid tumors. See an example of our work in this area here.

NIH R21CA252579
06/01/2021 – 05/31/2023

Water-soluble polymer-peptide biologics for fibronectin targeting in pulmonary fibrosis

The objective of this focus area is to investigate water-soluble PEGylated peptides for the imaging and treatment of pulmonary fibrosis, focusing on disruption of fibronectin fibrillogenesis and collagen deposition. See an example of our work in this area here.

DoD PRMR Program – Submitted
07/01/2022 – 06/30/2026

Active grant

Oligolactic Acid Prodrug-Based Nanomedicines for Cancer Therapy

Active grant

Targeting Tumor Fibrosis with a Potent Peptide Inhibitor of Fibronectin Assembly

Grant Submitted

PEGylated FN-Binding Peptide for Therapy and Imaging of Pulmonary Fibrosis

Milestones in Research and Achievements

1994

Jorge Heller Journal of Controlled Release/CRS Outstanding Paper Award

1998

American Association of Colleges of Pharmacy (AACP) Faculty New Investigator Award

1998

NIH FIRST Award

2003

CRS Young Investigator Research Achievement Award

2006

Invited Lecturer, 15th Nisshin Engineering Particle Technology International Seminar, Awaji, Japan

2012

Fellow of AAPS

2012

Distinguished Lecturer, Shizuoka DDS Conference, The Nagai Foundation, Japan

2013

20th PhD student (Hyunah Cho)

2013

Selection of Co-D Therapeutics for Emerging Company Showcase by BioForward, WI

2014

Highly Cited Researcher, Thomson Reuters, Pharmacology & Toxicology

2015

Orphan drug designation for Triolimus, 3-drug nanomedicine for the treatment of angiosarcoma

2016

AAPS PharmSciTech Outstanding Manuscript Award

2018

Founding of Wisconsin Center for Nanobiosystems (WisCNano)

2019

Paclitaxel prodrug enters NCL’s Laboratory Assay Cascade Characterization and Testing Program

2020

Editorial Board, Pharmaceutics